Leslie Burgess, MA

Leslie Burgess is a writer and member of the American Medical Writers Association living in Southern California. She has been working in the fields of science and medicine for more than 20 years and holds a BS in journalism from Monmouth University. Leslie is a volunteer for California State Parks and an avid photographer.

All articles by Leslie Burgess, MA

A new study provided firm evidence for the benefit of S-1 in treatment of patients with metastatic b

S-1 Prolongs Survival Compared With Taxanes for Treatment of Metastatic Breast Cancer

By

Leslie Burgess, MA

December 10, 2015

A new study provided firm evidence for the benefit of S-1 in treatment of patients with metastatic breast cancer (mBC).

Researchers have identified 55 genetic driver events involved in the development and progression of

Chronic Lymphocytic Leukemia

Large-Scale Genomic Analysis Gives New Insights Into the Chronology, Evolution of CLL

By

Leslie Burgess, MA

November 3, 2015

Researchers have identified 55 genetic driver events involved in the development and progression of CLL, including 2 not previously known to be involved in human cancer development.

Hospitalized patient

Higher Than Expected “Real-World” Hospitalizations Associated With Systemic Cancer Therapy

By

Leslie Burgess, MA

October 2, 2015

Patients receiving systemic therapy for metastatic non-small cell lung cancer (mNSCLC) outside of clinical trials are hospitalized significantly more often.

Agent Orange has long been associated with increased cancer rates among exposed veterans.

Multiple Myeloma

Veterans Exposed to Agent Orange Have Increased Risk for Monoclonal Gammopathy

By

Leslie Burgess, MA

September 9, 2015

Study confirmed the connection between Agent Orange exposure and development of monoclonal gammopathy of undetermined significance (MGUS).

Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often in

General Oncology

Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity

By

Leslie Burgess, MA

August 25, 2015

Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.

ASCO Endorses ASTRO Guidelines for Radiation Therapy Following Surgery for Endometrial Cancer

By

Leslie Burgess, MA

July 10, 2015

ASCO’s endorsement of the ASTRO guidelines for adjuvant radiotherapy for endometrial cancer provides additional guidance for clinicians.

Liver

Gastrointestinal Cancers

Nivolumab Shows Promising Efficacy, Safety in Advanced Hepatocellular Carcinoma

By

Leslie Burgess, MA

June 4, 2015

Patients with hepatocellular carcinoma (HCC) who have advanced on sorafenib have poor prognosis and few additional treatment options.

Options for treatment of patients with non-squamous NSCLC who progress after initial therapy are lim

Results of Nivolumab CheckMate 057 Study May Change Treatment of Lung Cancer

By

Leslie Burgess, MA

June 3, 2015

Options for treatment of patients with non-squamous non-small cell lung cancer (NSCLC) who progress after initial therapy are limited.

How frequent are mutations in known breast cancer predisposition genes in women with TNBC who were u

BRCA1/2 and Other Breast Cancer Gene Mutations in Patients Unselected for Family History

By

Leslie Burgess, MA

January 19, 2015

How frequent are mutations in known breast cancer predisposition genes in women with TNBC who were unselected for family history?

Survival Improved With Evolving Treatment Approaches for Metastatic Melanoma

Survival Improved With Evolving Treatment Approaches for Metastatic Melanoma

By

Leslie Burgess, MA

December 16, 2014

Update on available treatment options and potential future developments for metastatic melanoma with and without BRAF mutations.

Next post in Skin Cancer

Researchers Identify Neo-Antigens as Potential Targets for Personalized Immunotherapy

Melanoma Immunotherapy Slows Tumor Growth and Improves Survival in Mice